Abstract | BACKGROUND: OBJECTIVES: The purpose of this study was to assess whether Lp(a)-associated ASCVD risk is modified by hsCRP in the context of primary prevention. METHODS: The current study included 4,679 participants from the MESA (Multi-Ethnic Study of Atherosclerosis) Apolipoprotein ancillary data set. Cox proportional hazards models and Kaplan-Meier curves were used to assess the association among Lp(a), hsCRP, and time to cardiovascular disease (CVD) events. RESULTS: During a mean follow-up of 13.6 years, 684 CVD events occurred. A significant interaction was observed between Lp(a) and hsCRP (P = 0.04). With hsCRP <2 mg/L, no significant CVD risk was observed at any level of Lp(a) from <50 mg/dL to >100 mg/dL. However, with hsCRP ≥2 mg/L, a significant CVD risk was observed with Lp(a) of 50-99.9 mg/dL (HR: 1.36; 95% CI: 1.02-1.81) and Lp(a) ≥100 mg/dL (HR: 2.09; 95% CI: 1.40-3.13). Isolated elevations of either Lp(a) or hsCRP were not associated with increased CVD risk. In contrast, the combination of elevated Lp(a) (≥50 mg/dL) and hsCRP (≥2 mg/L) was independently associated with significant CVD risk (HR: 1.62; 95% CI: 1.25-2.10) and all-cause mortality (HR: 1.39; 95% CI: 1.12-1.72). CONCLUSIONS: Lp(a)-associated ASCVD risk is observed only with concomitant elevation of hsCRP. Individuals with concomitant presence of elevated Lp(a) and systemic inflammation have greater ASCVD risk and all-cause mortality, and thus may merit closer surveillance and more aggressive ASCVD risk management.
|
Authors | Wei Zhang, Jaime Lynn Speiser, Fan Ye, Michael Y Tsai, Miguel Cainzos-Achirica, Khurram Nasir, David M Herrington, Michael D Shapiro |
Journal | Journal of the American College of Cardiology
(J Am Coll Cardiol)
Vol. 78
Issue 11
Pg. 1083-1094
(09 14 2021)
ISSN: 1558-3597 [Electronic] United States |
PMID | 34503676
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Lipoprotein(a)
- C-Reactive Protein
|
Topics |
- Aged
- Aged, 80 and over
- Atherosclerosis
(blood, ethnology)
- C-Reactive Protein
(metabolism)
- Cohort Studies
- Female
- Heart Disease Risk Factors
- Humans
- Lipoprotein(a)
(blood)
- Male
- Middle Aged
- Mortality
- United States
(epidemiology)
|